Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

Rituximab 208Cyclophosphamide 167Etoposide 83Prednisone 79Vincristine 77Doxorubicin 76Peripheral Blood Stem Cell Transplantation 61Filgrastim 55Cytarabine 47fludarabine phosphate 46Radiotherapy 43Lenalidomide 41Mycophenolic Acid 40Tacrolimus 36Methotrexate 35Melphalan 35Busulfan 35Gemcitabine 32Carmustine 32Cyclosporine 31Whole-Body Irradiation 29Ifosfamide 28Antilymphocyte Serum 26zanubrutinib 25polatuzumab vedotin 25Dexamethasone 23Methylprednisolone 22ibritumomab tiuxetan 20Carboplatin 20Oxaliplatin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large B-Cell, Diffuse × Thalidomide × Clear all
NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡